Bioventus Inc.
Close on Oct 19, 2026
- Market cap
- $955.61M
- P/E (TTM)
- 17.5
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 27, 2026 | Aug 5, 2026 | Before market open | $153.20M | $0.47 | $0.22 |
| Q1 FY2026 Ended Mar 28, 2026 | May 6, 2026 | Before market open | $132.10M | $0.04 | $0.15 |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | Before market open | $157.90M | $0.21 | $0.24 |
| Q3 FY2025 Ended Sep 27, 2025 | Nov 4, 2025 | Before market open | $138.70M | $0.05 | $0.15 |
| Q2 FY2025 Ended Jun 28, 2025 | Aug 6, 2025 | Before market open | $147.70M | $0.11 | $0.21 |
| Q1 FY2025 Ended Mar 29, 2025 | May 6, 2025 | Before market open | $123.90M | $-0.04 | $0.08 |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 11, 2025 | Before market open | $153.60M | $0.00 | $0.15 |
| Q3 FY2024 Ended Sep 28, 2024 | Nov 5, 2024 | Before market open | $139.00M | $-0.07 | $0.06 |
| Q2 FY2024 Ended Jun 29, 2024 | Aug 6, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 30, 2024 | May 7, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 12, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EPS*non-GAAP | twelve months ending December 31, 2026 | $0.75 to $0.79 | Maintained |
| Cash from Operations | twelve months ending December 31, 2026 | $84.00M to $89.00M | Maintained |
| Net sales | twelve months ending December 31, 2026 | $600.00M to $610.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Bioventus filed with the SEC
Bioventus Reports Second Quarter Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Bioventus Reports First Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Bioventus Reports Third Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Bioventus Reports Second Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
Other events · EX-99.1 to Form 8-K
Bioventus Reports First Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
Bioventus Reports Third Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
Material agreement · Other events · EX-99.1 to Form 8-K
Bioventus Reports Second Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Bioventus Reports First Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Bioventus Names Robert Claypoole as President and Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Bioventus Completes Divestiture of its Wound Business
Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Acquisition or disposition completed · Other events · EX-99.2 to Form 8-K
Bioventus Reports First Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Bioventus Announces Divestiture of its Wound Business
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Bioventus Reschedules Earnings Call to May 16, 2023
Results of operations · EX-99.1 to Form 8-K